Decisiondx®-melanoma test ordered more than 200,000 times for patients diagnosed with cutaneous melanoma

Friendswood, texas, april 28, 2025 (globe newswire) -- castle biosciences, inc. (nasdaq: cstl), a company improving health through innovative tests that guide patient care, today announced its achievement of surpassing a significant milestone of 200,000 decisiondx-melanoma clinical test orders. decisiondx-melanoma is a 31-gene expression profile test that provides comprehensive, personalized results designed to improve risk-aligned management decisions for patients with stage i-iii cutaneous melanoma.
CSTL Ratings Summary
CSTL Quant Ranking